Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZURE: BLU-263 Monotherapy and Combination with Azacitidine in KIT-altered Hematologic Malignancies
2023-510144-20-00Phase 2Completed
- Sponsor
- Blueprint Medicines
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of elenestinib and azacitidine in systemic mastocytosis (SM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), mast cell leukemia (MCL) and 3 more (2 arms), sponsored by Blueprint Medicines. Primary endpoints: Recommended dose determination for BLU-263 monotherapy (Arm 1, dose escalation), Safety profile of BLU-263 monotherapy (Arm 1, dose escalation and expansion) and 4 more. Started Mar 2024; status: completed.
02
Drugs
elenestinibazacitidine
03
Conditions
systemic mastocytosis (SM)systemic mastocytosis with associated hematological neoplasm (SM-AHN)mast cell leukemia (MCL)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)myeloid/lymphoid neoplasm with eosinophilia and FLT3 rearrangement
Beyond the preview
Go deeper on 2023-510144-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510144-20-00.